Table 4. Summary ORs and 95% CI of microRNA-499 rs3746444 polymorphisms and CHD risk.
| Locus | N* | Allele | Recessive | Dominant | Homozygote | Heterozygote | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) P | I2(%) | OR (95%CI) P | I2(%) | OR (95%CI) P | I2(%) | OR (95%CI) P | I2(%) | OR (95%CI) P | I2(%) | ||
| Total | 6 | 1.11 (1.02-1.20) 0.015 | 17.8 | 1.55 (1.07-2.27) 0.022 | 58.1 | 1.03 (0.94-1.13) 0.545 | 0 | 1.54 (1.08-2.20) 0.017 | 52.6 | 0.95 (0.85-1.05) 0.275 | 21.8 |
| Source of controls | |||||||||||
| Population | 1 | 1.13 (0.94-1.36) 0.199 | NA | 1.12 (0.66-1.91) 0.676 | NA | 1.15 (0.93-1.42) 0.193 | NA | 1.16 (0.68-1.98) 0.588 | NA | 1.15 (0.92-1.43) 0.218 | NA |
| Hospital | 5 | 1.10 (1.01-1.21) 0.039 | 33.7 | 1.68 (1.11-2.55) 0.014 | 55.9 | 1.00 (0.90-1.12) 0.990 | 0 | 1.65 (1.10-2.46) 0.015 | 52.4 | 0.90 (0.80-1.01) 0.061 | 0 |
| Method | |||||||||||
| Taqman | 2 | 1.15 (1.01-1.32) 0.042 | 0 | 1.46 (1.02-2.10) 0.038 | 42.7 | 1.12 (0.96-1.31) 0.156 | 0 | 1.48 (1.03-2.12) 0.034 | 30.1 | 1.07 (0.90-1.26) 0.446 | 0.8 |
| PCR-RFLP | 3 | 1.03 (0.90-1.17) 0.693 | 48.8 | 1.24 (0.42-3.66) 0.693 | 77.9 | 0.93 (0.79-1.08) 0.330 | 0 | 1.20 (0.42-3.39) 0.737 | 76.1 | 0.84 (0.71-0.99) 0.033 | 0 |
| Age and sex matched | 4 | 1.10 (1.00-1.22) 0.052 | 27.5 | 1.51 (0.89-2.57) 0.127 | 71.1 | 1.03 (0.92-1.15) 0.631 | 0 | 1.49 (0.91-2.45) 0.113 | 66.5 | 0.94 (0.79-1.12) 0.493 | 52.7 |
| Controls in HWE | 4 | 1.08 (0.98-1.20) 0.132 | 45.2 | 1.55 (0.86-2.79) 0.144 | 66.9 | 0.98 (0.87-1.11) 0.744 | 0 | 1.51 (0.85-2.66) 0.159 | 64.3 | 0.88 (0.77-1.00) 0.050 | 0 |
* Numbers of comparisons. PCR-RFLP: polymerase chain reaction-based restriction fragment length polymorphism. HWE: Hardy-Weinberg equilibrium. NA: not available.